Mineralys CEO awarded options and RSUs

Mineralys Therapeutics, Inc. reported that Chief Executive Officer Jon Congleton received new equity-based compensation on February 19, 2026.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. reported that Chief Executive Officer Jon Congleton received new equity-based compensation on February 19, 2026. He was granted 187,900 stock options, which vest in equal monthly installments over four years, with 1/48th of the total vesting each month after the grant date.

Congleton also acquired 140,900 shares of common stock through a grant of restricted stock units (RSUs) for no additional cash consideration. Each RSU represents one share of common stock and vests in four annual installments of 25% each on the yearly anniversaries of the grant date, bringing his direct common stock holdings to 780,051 shares.

Insider Trade Summary

Grant/Award: 328,800 shares

Grant/Award 2 txns

Insider Congleton Jon

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	187,900	$0.00	$0.00
Grant/Award	Common Stock	140,900	$0.00	$0.00

Holdings After Transaction: Stock Option — 187,900 contracts (Direct); Common Stock — 780,051 shares (Direct)

Footnotes (2)

1. F1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.
2. F2. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mineralys Therapeutics (MLYS) CEO Jon Congleton report on this Form 4?

Jon Congleton reported equity grants from Mineralys Therapeutics. He received 187,900 stock options and 140,900 restricted stock units, both awarded for no additional cash consideration, increasing his direct common stock holdings to 780,051 shares after the RSU grant.

How many stock options were granted to the Mineralys Therapeutics (MLYS) CEO?

The CEO received a grant of 187,900 stock options. These options vest in equal monthly installments over four years, with 1/48th of the total shares vesting each month following the February 19, 2026 grant date.

What common stock or RSU grant did Mineralys Therapeutics (MLYS) disclose for its CEO?

Mineralys Therapeutics granted Jon Congleton 140,900 restricted stock units, each representing one share of common stock. The RSUs vest over four years, with one-quarter of the total vesting on each annual anniversary of the grant date.

At what price were the Mineralys Therapeutics (MLYS) CEO’s new awards reported?

Both the 187,900 stock options and 140,900 restricted stock units were reported with a transaction price of $0.00 per share, reflecting that they were granted as compensation rather than purchased in an open-market transaction.

How do the Mineralys Therapeutics (MLYS) CEO’s new RSUs vest over time?

The 140,900 RSUs vest in four annual installments. One-quarter of the total shares underlying the RSU grant vests on each one-year anniversary of the February 19, 2026 grant date, contingent on the standard vesting conditions.

How do the Mineralys Therapeutics (MLYS) CEO’s new stock options vest?

The 187,900 stock options vest in monthly installments over four years. One forty-eighth of the total option shares vests each month following the February 19, 2026 grant date, according to the reported vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 07:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Congleton Jon

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		A		140,900(1)	A	$0	780,051	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$28.06	02/19/2026		A		187,900		(2)	02/19/2036	Common Stock	187,900	$0	187,900	D

Explanation of Responses:

1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.

2. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant

Remarks:

	/s/ Adam Levy, Attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.